A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2018
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2016 Status changed from recruiting to discontinued.
- 13 Oct 2015 According to the ClinicalTrials.gov record, chemotherapy regimen has been changed from FOLFIRINOX to gemcitabine, nab-paclitaxel and capecitabine; planned patient number changed from 288 to 346.